

Chitosan-Based Nanoparticles

Guest Editors:

**Dr. Mariadoss Arokia Vijaya
Anand**

Dr. Surendhiran Duraïarasan

Dr. Cédric Delattre

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editors

Dear Colleagues,

In the recent past, the biomedical research community has experienced unlimited benefit from nano-based therapeutic materials. In particular, chitosan-based nanomaterials have gained a great deal of attention in various fields, including the food, pharmaceutical, biomedical and environmental industries, owing to its safe profile, biocompatibility, and biodegradability nature. The uniqueness of its shape, size, and physiochemical features may augment the beneficial pharmacological activities. A series of recent studies have proven that chitosan is amongst the most studied and researched biomaterials. Therefore, this Special Issue will unite researchers, translational scientists, and physicians to address all the aspects of marine-derived chitosan-based nanomaterials, beyond the structural, functional, therapeutic and biomedical applications. We also welcome critical reviews from the experts in these subjects. All submissions should be related to marine-derived chitosan.

I'm looking forward to hearing from you soon.


Dr. Mariadoss Arokia Vijaya Anand

Dr. Surendhiran Duraïarasan

Dr. Cédric Delattre

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmacology, Toxicology and Pharmaceutics (miscellaneous)*)

Contact Us

Marine Drugs Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
X@Marine_Drugs